Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Mostafa Elwany
Based on 3 articles published since 2010
(Why 3 articles?)

Between 2010 and 2020, Mostafa Elwany wrote the following 3 articles about Coronary Artery Disease.
+ Citations + Abstracts
1 Review Treatment of coronary bifurcation lesions: current knowledge and future perspectives. 2018

Elwany, Mostafa / Palma, Gaetano Di / Cortese, Bernardo. ·Interventional Cardiology, ASST Fatebenefratelli-Sacco, Milano, Italy. · Faculty of Medicine, University of Alexandria, Alexandria, Egypt. · Department of Cardiothoracic Sciences, Second University of Napoli, Naples, Italy. · Cardiac Department, Fondazione G Monasterio CNR-Regione Toscana, Pisa, Massa, Italy. ·Future Cardiol · Pubmed #29372810.

ABSTRACT: Coronary lesions at bifurcation sites are frequent and still remain a challenging subset for the interventional cardiologist. Although in the last years the provisional stenting technique has shown more consistent results, coronary bifurcation interventions still share a worse procedural success rate and increased rates of mid- and long-term cardiac events. Most of the dedicated devices proposed in the last few years have failed to show improved results when compared with standard devices. The broader use of imaging techniques, such as intravascular ultrasound and optical coherence tomography, lead to a better understanding of the real anatomy of bifurcations and has shown to be a great tool for percutaneous coronary intervention optimization. Preliminary results come from drug-coated balloons and bioresorbable vascular scaffolds, especially for the 'leave nothing behind' concept, particularly interesting in this setting of lesions.

2 Article Clinical and angiographic outcome of a single center, real world population treated with a dedicated technique of implantation for bioresorbable vascular scaffolds. The FAtebenefratelli Bioresorbable Vascular Scaffold (FABS) registry. 2017

Cortese, Bernardo / di Palma, Gaetano / Cerrato, Enrico / Latini, Roberto A / Elwany, Mostafa / Orrego, Pedro S / Seregni, Romano G. ·Unità Operativa di Cardiologia, ASST Fatebenefratelli-Sacco, Milano, Italy. · Fondazione Monasterio-Regione Toscana-Centro Nazionale delle Ricerche, Pisa and Massa, Italy. · Division of Cardiology, Cardio-thoracic and Respiratory Sciences Department, Second University of Naples, AO Dei Colli-Monaldi Hospital, Naples, Italy. · San Luigi Gonzaga University Hospital, Orbassano (Turin), Italy. ·J Interv Cardiol · Pubmed #28853189.

ABSTRACT: OBJECTIVES: With this prospective study we aim at investigating the long-term outcome of a consecutive cohort of patients successfully treated with bioresorbable scaffold (BVS) implantation. BACKGROUND: It is not clearly understood if there is a relation between the technique of BVS implantation and the outcome. METHODS: Between December 2012 and December 2014, all consecutive patients treated with BVS were included in this registry and received an angiographic follow-up. After a run-in phase, all BVS were implanted using a specific technique consisting of aggressive predilation, correct scaffold sizing, visually determined, and high-pressure post-dilation with a noncompliance balloon. Primary endpoint was late lumen loss (LLL) at 1-year angiographic follow-up and ischemia-driven target-lesion revascularization (ID-TLR) at 2-year clinical follow-up. Secondary endpoints were the occurrence of binary restenosis, major adverse cardiac events (MACE), and every single component of MACE (cardiac death, myocardial infarction, TLR) at 2 years. RESULTS: A total of 144 lesions in 122 patients treated consecutively with BVS, were enrolled. Diabetics were 29.5% and acute coronary syndrome at presentation occurred in 29.5% of patients. At the angiographic follow-up LLL was 0.38 ± 0.9. At 2-year clinical follow-up, ID-TLR occurred in eight patients (5.6%). We observed two cases of scaffold thrombosis (1.38%, one early and one very late). At multivariate statistical analysis, STEMI presentation remained a significant predictor for TLR. CONCLUSIONS: In a complex, all-comers real world population, BVS implantation with a specific, and standardized technique showed to be feasible, with acceptable mid-term angiographic and long-term clinical outcome.

3 Unspecified Fracture with the newer bioresorbable vascular scaffolds. 2017

Elwany, Mostafa / Di Palma, Gaetano / Cortese, Bernardo. ·Interventional Cardiology, A.O. Fatebenefratelli, Milano, Italy. · Faculty of medicine, Alexandria University, Alexandria, Egypt. · Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Massa, Italy. ·Catheter Cardiovasc Interv · Pubmed #28295999.

ABSTRACT: Bioresorbable vascular scaffolds (BVS) are being increasingly used in complex, real-world lesions. The possibility of strut fractures is a rare entity with the use of drug eluting stents (DES), but has not yet been adequately described for the BVS technology. In this report, we present a case of scaffold fracture of DEsolve BVS (Elixir Medical Corporation, USA) that was diagnosed both angiographically and by optical coherence tomography(OCT). Scaffold fracture with the newer BVS is a new Achilles' heel in the BVS technology. This gap in knowledge about the etiology such as over-expansion and potential predictors of strut fracture need to be deeply investigated before a widespread use of such technologies is adopted. © 2017 Wiley Periodicals, Inc.